Phase II Single Arm study of AZD9291 to treat NSCLC patients in Asia Pacific

Trial Identifier:	D5160C00017
Sponsor:	AstraZeneca
NCTID::	NCT02442349
Start Date:	June 2015
Primary Completion Date:	March 2016
Study Completion Date:	December 2023
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433
CN	Shanghai, CN, CN-200433

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company